RxDoctor Payments Data

Kayla Metz, APRN

Nurse Practitioner · Clarksville, ARNPI 1891375838

Payments from drug & device makers

$1,262in general payments, 2019–2025

Across 66 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$459
  • Novo Nordisk$170
  • Pfizer$105
  • AstraZeneca$99
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$76
  • GSK$62
  • plus $290 from 11 others

What the payments were for

  • Food & beverage$1,262100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,262 in reported general payments places this provider in the 75th percentile of 697 nurse practitioner providers in Arkansas.

See all nurse practitioner providers in Arkansas

Medicare billing

Part B allowed, 2024
$15,724
Medicare patients
91
Services billed
332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$11,957
ValacyclovirValacyclovir Hcl14$1,888
Celecoxib23$1,305
Pantoprazole Sodium49$987
Albuterol Sulfate HfaAlbuterol Sulfate47$860
Omeprazole28$661
Atorvastatin Calcium33$559
Sucralfate13$524
Promethazine Hcl17$426
Cefdinir21$387
Levetiracetam12$386
Metoprolol Succinate24$363
Famotidine23$317
Levothyroxine Sodium25$315
Alendronate Sodium37$310

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$62$11,95718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 697 nurse practitioner providers in Arkansas.

Other nurse practitioner in Clarksville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →